Cloud

Cloud Investing

YDreams Med S.L. (“YDreams Med”) issues this press release pursuant to Part 3.1 of National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues with respect to YDreams Global Interactive Technologies Inc. (the “Company”) (TSXV:YD).

YDreams Med S.L. (“YDreams Med”) issues this press release pursuant to Part 3.1 of National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues with respect to YDreams Global Interactive Technologies Inc. (the “Company”) (TSXV:YD).
On November 23, 2017, pursuant to share transfer agreements with five purchasers, YDreams Med disposed of an aggregate of 2,900,000 common shares of the Company (the “Common Shares”) for an aggregate purchase price of $232,000 (the “Transaction”). The purchasers paid the purchase price by off-setting against promissory notes issued by YDreams Med to the purchasers in the aggregate amount of $232,000.
Prior to the Transaction, YDreams Med owned and controlled the following securities:
17,550,000 Common Shares;
6,500,000 share purchase warrants (the “Warrants”) to purchase an additional 6,500,000 Common Shares.
Prior to the Transaction, YDreams Med owned and controlled 24,050,000 Common Shares, on a partially diluted basis (assuming exercise of all Warrants), which represented 35.9% of the Common Shares outstanding on a partially diluted basis prior to the Transaction, comprised of: (i) 60,578,311 Common Shares outstanding prior to the completion of the Transaction and (ii) 6,500,000 Common Shares that may be issuable on exercise of Warrants.
Following the Transaction, YDreams Med owns and controls an aggregate of:
14,650,000 Common Shares;
6,500,000 Warrants to purchase an additional 6,500,000 Common Shares.
After the disposition of the Common Shares, YDreams Med owns and controls 21,150,000 Common Shares, on a partially diluted basis (assuming exercise of all Warrants), which represents 31.5% of the Common Shares outstanding on a partially diluted basis following completion of the Transaction, comprised of: (i) 60,578,311 Common Shares outstanding following the completion of the Transaction and (ii) 6,500,000 Common Shares that may be issuable on exercise of Warrants.
Mr. Jose Miguel Rodrigues Remedio, a director of the Company, is the sole director of YDreams Med. As such, the Common Shares and Warrants held by YDreams Med should be considered to be under the control and direction of Mr. Remedio. Mr. Remedio does not own any securities of the Company in a personal capacity.
The Common Shares were disposed of for investment purposes. Depending on economic or market conditions or matters relating to the Company or YDreams Med, YDreams Med may choose to either acquire additional securities or dispose of securities of the Company.
YDREAMS MED S.L.
Per: “Jose Miguel Rodrigues Remedio”
JOSE MIGUEL RODRIGUES REMEDIO
DIRECTOR
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Click here to connect with YDreams Global Interactive Technologies (TSXV:YD) for an Investor Presentation.

Source: www.stockwatch.com

MARKETS

Markets
TSX18834.16-194.70
TSXV615.94-7.29
DOW30967.82-129.44
S&P 5003831.39+6.06
NASD11322.24+194.39
ASX6612.60+72.70

COMMODITIES

Commodities
Gold1765.72-43.38
Silver19.23-0.75
Copper3.43-0.17
Palladium1938.00+0.50
Platinum869.00-15.01
Oil99.62-8.81
Heating Oil3.58-0.36
Natural Gas5.49-0.24

DOWNLOAD FREE REPORTS

×